This document is an initial statement of beneficial ownership of securities (Form 3) filed by Benjamin Cravatt, a director at ALNYLAM PHARMACEUTICALS, INC. The filing indicates that Benjamin Cravatt has acquired or is reporting beneficial ownership of securities. The report was signed on June 3, 2026, covering the peri...

This filing details a Limited Power of Attorney granted by Peter J. Pitts, a director of BRAINSTORM CELL THERAPEUTICS INC. (BCLI), to Matthew Leder and Joseph Nunziata. This power of attorney authorizes the appointees to act on Mr. Pitts' behalf for SEC reporting requirements, including obtaining EDGAR credentials, man...

This filing reports a Form 3, which indicates initial beneficial ownership, for Gwen Melincoff, a director at Chemomab Therapeutics Ltd. (CMMB). The report covers the period ending June 1, 2026. Melincoff was granted a stock option to buy American Depositary Shares (ADS) with an exercise price of $1.86 per share. The o...

This filing is an Exhibit 24, a Power of Attorney document for James Sapirstein, Chief Executive Officer of Cocrystal Pharma, Inc. (COCP). Sapirstein appoints James Martin and Michael D. Harris as his attorneys-in-fact. This grants them the authority to prepare and execute Forms 3, 4, and 5 for Sapirstein in accordance...

This document is an initial statement of beneficial ownership of securities (Form 3) filed by Benjamin Cravatt, a director at ALNYLAM PHARMACEUTICALS, INC. The filing indicates that Benjamin Cravatt has acquired or is reporting beneficial ownership of securities. The report was signed on June 3, 2026, covering the peri...